Omnix Medical is a clinical-stage biopharmaceutical company developing next-generation of anti-infective drugs. We are determined to provide a safer, more efficient alternative to win the battle against AMR by offering therapies that are, by design, resilient against resistance development. Omnix Medical was founded in 2015 to address the urgent unmet need for new life-saving anti-infective drugs. Omnix´ proprietary technology eliminates bacteria by mimicking the innate immune system of insects which uses unique molecules to kill resistant bacterial strains efficiently and selectively without toxic effects. Omnix´ technology prevents the development of new resistances and is thus well positioned to become a first-line-treatment in a highly unmet need. The Company’s lead compound, OMN6, is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 is being developed for the treatment of life-threatening hospital-acquired infections (HIA) caused by the Gram-negative bacteria Acinetobacter baumannii, and has shown significantly higher potency than currently available treatments. Recently, Omnix has initiated a Phase 2 Proof-of-Concept trial of the company´s novel anti-infective OMN6 in HABP/VABP patients under IND approval from the FDA. Omnix team is hard at work with several active sights for the Phase 2 clinical trial as well as advancing our pipeline molecules and our mission to introduce new life-saving anti-infectives.